Nothing (Im)personal

Nothing (Im)personal

With unprecedented numbers of practices locking out sales reps, pharma companies are being forced to do a better job of engaging HCPs in other ways

Five things for pharma marketers to know: Thursday, January 29

Five things for pharma marketers to know: Thursday, January 29

Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.

Biogen adds football, basketball talent for MS campaign

Biogen adds football, basketball talent for MS campaign

MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Five things for pharma marketers to know: Wednesday, January 28

Five things for pharma marketers to know: Wednesday, January 28

Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.

Therapeutic Focus: Rare Diseases

Therapeutic Focus: Rare Diseases

The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge.

Mobile Marketing Report: On Hold

Mobile Marketing Report: On Hold

It's not as though pharma marketers didn't see mobile coming. For the past half decade, they've discussed its potential to transform behaviors and relationships within the healthcare ecosystem. Yet now that mobile has arrived, they find themselves torn between caution and exuberance. Larry Dobrow explains

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

Hysingla ER is ready for the marketplace, just two months after FDA approval.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

P&G's Zzzquil accused of sexist tweet

The nighttime sleep aid's Twitter account wrote "Sleep LIKE he finally proposed," last week, a sentiment which didn't resonate positively with the feed's followers.

Drugmaker enlists Fitbit to better understand patients

Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

NPS drug approval bolsters Shire acquisition decision

NPS drug approval bolsters Shire acquisition decision

The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Headliner: Scientist CEO sets sights on Sierra Leone

Headliner: Scientist CEO sets sights on Sierra Leone

Thomas Sack, President and CEO, MRIGlobal

Five things for pharma marketers to know: Friday, January 23

Five things for pharma marketers to know: Friday, January 23

Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

Five things for pharma marketers to know: Thursday, January 22

Five things for pharma marketers to know: Thursday, January 22

Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.

Novartis psoriasis drug approval could upend market

Novartis psoriasis drug approval could upend market

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

Nurse practitioner workforce has just about doubled

Marketers may want to dust off plans to create NP-centric materials.

Five things for pharma marketers to know: Wednesday, January 21

Five things for pharma marketers to know: Wednesday, January 21

President Barack Obama says personalized medicines need financial support in SOTU Address; Salix explores M&A options; lobbying groups PhRMA and BIO say generic painkillers without abuse-deterrent features should be pulled from shelves.

Sandoz gets ready to make the biosimilar case with oncologists

Sandoz gets ready to make the biosimilar case with oncologists

Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.

J&J Q4 sales slip, but year finishes up 4.2%

J&J Q4 sales slip, but year finishes up 4.2%

Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.

AbbVie to discount HCV drugs for state HIV programs

A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

Five things for pharma marketers to know: Friday, January 16

Five things for pharma marketers to know: Friday, January 16

CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.

From Misfits to FitBits: CES 2015, The CLINICAL Electronics Show

From Misfits to FitBits: CES 2015, The CLINICAL Electronics Show

Key trends from the latest Consumer Electronics Show through the eyes of NostaLab's John Nosta

FDA appoints Office of Generic Drugs director

FDA has named Kathleen Uhl as permanent director of the Office of Generic Drugs.

BI weighs sale of generic business

Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.

Abandonment rates indicate room in the anti-TNF market

Abandonment rates indicate room in the anti-TNF market

Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.

Five things for pharma marketers to know: Thursday, January 15

Five things for pharma marketers to know: Thursday, January 15

Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

Getting Your Big Ideas to Work in Pharma Advertising

Getting Your Big Ideas to Work in Pharma Advertising

Stop trying to sell your edgy work as a TV spot. By finding a backdoor through digital, risky work can often see the light of day, says one ad consultant.

Roche's scuttled cholesterol drug may work

Clinical trials indicate the CTEP works for specific genetic profiles.

Five things for pharma marketers to know: Wednesday, January 14

Five things for pharma marketers to know: Wednesday, January 14

Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.

Havas acquires health and wellness agency

Havas acquires health and wellness agency

Havas Group has expanded its footprint in Germany, acquiring Bird & Schulte.

FDA to study impact of shorter DTC risk list

FDA to study impact of shorter DTC risk list

The FDA is looking into whether abbreviated risk information is a good idea for DTC.

Five things for pharma marketers to know: Tuesday, January 13

Five things for pharma marketers to know: Tuesday, January 13

Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.

Pfizer challenges Novartis OTC ad claims

Pfizer challenges Novartis OTC ad claims

Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'

News hints at BMS-Merck PD-1 lung cancer tussle

News hints at BMS-Merck PD-1 lung cancer tussle

News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.

NFL players promote Healthcare.gov

HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Five things for pharma marketers to know: Monday, January 12

Five things for pharma marketers to know: Monday, January 12

BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.

Playing to Win in the Global Biosimilars Environment

Playing to Win in the Global Biosimilars Environment

"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."

Five things for pharma marketers to know: Friday, January 9

Five things for pharma marketers to know: Friday, January 9

Regeneron/Sanofi PCSK9 meets Phase-III endpoint; Anthem selects Gilead's Harvoni as primary HCV treatment; GSK and Merck about to begin human trials for Ebola vaccine.

Alkermes mid-stage antipsychotic stays on track

A Phase-II study showed the schizophrenia drug performed as well as, but without the weight gain associated with, an older treatment.

AbbVie female health drug's success hinges on safety

AbbVie female health drug's success hinges on safety

AbbVie announced positive interim Phase-III results Thursday for its endometriosis drug elagolix, but one analyst says its commercial impact is likely linked to its effect on patients' bone mineral density.

Mallinckrodt plans expansion of commercial staff

The specialty biopharma firm says it's hiring new commercial managers after a buying spree.

Pfizer cancer drug skips FDA advisory panel

Pfizer cancer drug skips FDA advisory panel

The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.

Five things for pharma marketers to know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Orphan-focused shop Siren Interactive scooped up by life-sci services firm

Orphan-focused shop Siren Interactive scooped up by life-sci services firm

Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen's patient-care model.

Patient survey indicates promise of EHR

Patient survey indicates promise of EHR

The fifth annual Xerox survey of patients and electronic health records shows patients have high expectations for the digital data.

Gates Foundation sponsors campaign to promote vaccinations

The artwork is meant to inspire debate and donations for vaccinations.

Novartis to leverage DNA-editing tool for immunotherapy

The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.

Five things for pharma marketers to know Wednesday, January 7

Five things for pharma marketers to know Wednesday, January 7

India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.

As predicted, Gilead strikes hep.-C pact with CVS

Countering Express Scripts' exclusive status for AbbVie's hep.-C entry, CVS/Caremark makes Harvoni and Sovaldi preferred choices on its drug lists.

2013 healthcare spending crept upwards

2013 healthcare spending crept upwards

Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.

Mylan enters generic Diovan fray

The drugmaker launched four doses of the blood pressure medication.

Patients lie on EMRs

Clemson University researchers found that patients are not all that honest with healthcare providers.

Five things for pharma marketers to know: Tuesday, January 6

Five things for pharma marketers to know: Tuesday, January 6

Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.

Get the most out of your digital detailing efforts in 2015

Get the most out of your digital detailing efforts in 2015

"Technology is evolving in a way that will make your detailing experiences even more meaningful. 2015 will bring in some exciting and innovative products..."

FDA panel to weigh first biosimilar application

FDA panel to weigh first biosimilar application

The committee is slated to rule on Sandoz's Zarzio Jan 7.

J&J subsidiary inks $35M RNA deal

The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.

Talking, braille labels to show up in mailboxes

A CVS Health/American Council of the Blind collaboration means some visually impaired patients will soon have more engaging prescription labels.

Novo CEO is looking for the exits

Rebien Soerensen told a Danish paper that he expects to leave his position before 2019.

Five things for pharma marketers to know: Monday, January 5

Five things for pharma marketers to know: Monday, January 5

Severe flu season to test Roche's Tamiflu; Novartis gains nod for psoriasis drug; Amgen and Kite collaborate on immunotherapy.

Private View: Norm Alger

Private View: Norm Alger

"Here are some examples of some elegant initiatives from some very smart people to put a substantial stake in the ground toward these rather monumental global [health] efforts."

Read the complete January 2015 Digital Edition

Click the above link to access the complete Digital Edition of the January 2015 issue of MM&M, with all text, charts and pictures.

The Top 40 Healthcare Transformers

The Top 40 Healthcare Transformers

Change within a set-in-its-ways industry can be scary—that is, unless you've got the will and bravado to tackle it head-on. Here are the 40 inventors, ­strategists, advocates and wonks who are challenging, disrupting and otherwise transforming the healthcare business.

Phone-free connections?

Phone-free connections?

At any well-run business meeting, a smartphone is not only disruptive but also signals that its user is less than fully engaged with the business at hand

DDR on DTC: AZ's Crestor

DDR on DTC: AZ's Crestor

Is Crestor the new Energizer Bunny?

At Work With: Michelle Keefe

At Work With: Michelle Keefe

COO, Publicis Touchpoint Solutions

Upward Move: Mark Friedman

Upward Move: Mark Friedman

Mark Friedman, EVP, chief creative officer, Harrison and Starr

How to get clients to rethink the status quo

How to get clients to rethink the status quo

We need to help our health systems and healthcare companies function like agile start-ups

Is pharma equipped to prove value?

Delivering better patient outcomes takes the right economic instruments. Do market-access teams have the right tools at their disposal to make the value-for-money argument?

Purdue CCO makes a drive for diversity

Purdue CCO makes a drive for diversity

Adding skills diversity to Purdue's talent base is an important goal

Disruption on display

Disruption on display

As these 40 standouts show, the industry is ready to move forward

Communication Shakedown

Communication Shakedown

Long the only game in town, health insurers—many have observed—never mastered the art of customer service. But with a host of tech- and service-savvy upstarts making plays for "their" customers, the rules have changed. Sarah Mahoney examines how the new breed of insurers—who mix high tech with high touch—are trying to outflank the establishment

Washington Insider

Washington Insider

One issue lurking for marketers is the potential elimination of the tax exemption for advertising

"I" in the Sky

"I" in the Sky

In theory, healthcare marketers love the idea of beacons. In practice? Well, nobody's sure whether patients and physicians will be wowed by their utility or turned off by their invasiveness. Barbara Peck offers a Beacons 101 primer

MM&M's top reads of 2014

MM&M's top reads of 2014

A look at the content that grabbed most reader interest over the past year.

Five things for pharma marketers to know: Wednesday, December 31

Five things for pharma marketers to know: Wednesday, December 31

Pop songs about doctors get heavy rotation in BMJ; digital-health investment tally shows doubling in 2014; scientists finger bats as possible Ebola source.

Novo seeks to make Saxenda a familiar name in weight loss

Novo seeks to make Saxenda a familiar name in weight loss

The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.

Kalydeco gains expanded use

The cystic fibrosis drug adds approval for treating a 10th gene mutation.

Five things for pharma marketers to know: Tuesday, December 30

Five things for pharma marketers to know: Tuesday, December 30

NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.

Breakthrough drugs post banner year

Nine drugs that promised meaningful advances over existing treatments earned the coveted status from FDA and were approved.

Who will win the Opdivo-Keytruda coverage clash?

Who will win the Opdivo-Keytruda coverage clash?

A focus on the existing Yervoy prescribing community could help Bristol-Myers Squibb drive sales of Opdivo past rival Keytruda, one analyst argues.

Five things for pharma marketers to know: Monday, December 29

Five things for pharma marketers to know: Monday, December 29

FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.

Early Opdivo OK gives BMS more time to erase Keytruda's lead

Early Opdivo OK gives BMS more time to erase Keytruda's lead

FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.

Gilead may be forced to discount hep. C pills

AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters